FDA expands approval of Adcetris for Stage III or IV classical Hodgkin lymphoma

10:15 EDT 23 Mar 2018 | European Pharmaceutical Review

Adcetris

The FDA has approved Adcetris to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma in combination with chemotherapy...

The post FDA expands approval of Adcetris for Stage III or IV classical Hodgkin lymphoma appeared first on European Pharmaceutical Review.

Original Article: FDA expands approval of Adcetris for Stage III or IV classical Hodgkin lymphoma

NEXT ARTICLE

More From BioPortfolio on "FDA expands approval of Adcetris for Stage III or IV classical Hodgkin lymphoma"